CN117222437A - 构象切换的纳米结构 - Google Patents
构象切换的纳米结构 Download PDFInfo
- Publication number
- CN117222437A CN117222437A CN202280030065.3A CN202280030065A CN117222437A CN 117222437 A CN117222437 A CN 117222437A CN 202280030065 A CN202280030065 A CN 202280030065A CN 117222437 A CN117222437 A CN 117222437A
- Authority
- CN
- China
- Prior art keywords
- nanostructure
- molecule
- coupling
- entity
- sites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169934.3A EP4079330A1 (en) | 2021-04-22 | 2021-04-22 | Conformation switching nanostructures |
| EP21169934.3 | 2021-04-22 | ||
| PCT/EP2022/060737 WO2022223802A1 (en) | 2021-04-22 | 2022-04-22 | Conformation switching nanostructures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117222437A true CN117222437A (zh) | 2023-12-12 |
Family
ID=75659780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280030065.3A Pending CN117222437A (zh) | 2021-04-22 | 2022-04-22 | 构象切换的纳米结构 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240199763A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4079330A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024515346A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230175241A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117222437A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022223802A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4399528A1 (en) | 2021-09-09 | 2024-07-17 | Nautilus Subsidiary, Inc. | Characterization and localization of protein modifications |
| EP4764494A1 (en) * | 2024-12-20 | 2026-06-24 | Plectonic Biotech GmbH | Conjugates for analyte detection and quantification |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020254684A1 (en) * | 2019-06-21 | 2020-12-24 | Tilibit Nanosystems Gmbh | Conditionally switchable nanostructure |
-
2021
- 2021-04-22 EP EP21169934.3A patent/EP4079330A1/en not_active Withdrawn
-
2022
- 2022-04-22 US US18/287,269 patent/US20240199763A1/en active Pending
- 2022-04-22 EP EP22724742.6A patent/EP4326342A1/en active Pending
- 2022-04-22 JP JP2023564438A patent/JP2024515346A/ja active Pending
- 2022-04-22 KR KR1020237039385A patent/KR20230175241A/ko active Pending
- 2022-04-22 WO PCT/EP2022/060737 patent/WO2022223802A1/en not_active Ceased
- 2022-04-22 CN CN202280030065.3A patent/CN117222437A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240199763A1 (en) | 2024-06-20 |
| EP4326342A1 (en) | 2024-02-28 |
| JP2024515346A (ja) | 2024-04-09 |
| KR20230175241A (ko) | 2023-12-29 |
| WO2022223802A1 (en) | 2022-10-27 |
| EP4079330A1 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rinoldi et al. | Nanotechnology‐assisted RNA delivery: from nucleic acid therapeutics to COVID‐19 vaccines | |
| Jain et al. | Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery | |
| Edwardson et al. | Virus-inspired function in engineered protein cages | |
| Yang et al. | Self-assembled double-bundle DNA tetrahedron for efficient antisense delivery | |
| Nagamune | Biomolecular engineering for nanobio/bionanotechnology | |
| van der Meel et al. | Next-generation materials for nucleic acid delivery | |
| Panté et al. | Nuclear pore complex is able to transport macromolecules with diameters of∼ 39 nm | |
| Céspedes et al. | In vivo architectonic stability of fully de novo designed protein-only nanoparticles | |
| CN108175759B (zh) | 一种抗肿瘤靶向给药系统及其制备方法与应用 | |
| Mukherjee et al. | Galactose functionalized mesoporous silica nanoparticles as delivery vehicle in the treatment of hepatitis C infection | |
| Chen et al. | Framework nucleic acid nanomaterials for central nervous system therapies: design for barrier penetration, targeted delivery, cellular uptake, and endosomal escape | |
| Liu et al. | Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles | |
| Shi et al. | Virus mimetic framework DNA as a non-LNP gene carrier for modulated cell endocytosis and apoptosis | |
| Yamada et al. | Development of a nanoparticle that releases nucleic acids in response to a mitochondrial environment | |
| US20240199763A1 (en) | Conformation switching nanostructures | |
| Menon et al. | Designer, Programmable DNA‐peptide hybrid materials with emergent properties to probe and modulate biological systems | |
| Nasu et al. | Nanopore-controlled dual-surface modifications on artificial protein nanocages as nanocarriers | |
| Ingle et al. | Polyplexes are endocytosed by and trafficked within filopodia | |
| Li et al. | Intranuclear delivery of DNA nanostructures via cellular mechanotransduction | |
| Tang et al. | Augmenting the Precise Targeting of Antimicrobial Peptides (AMPs) and AMP‐Based Drug Delivery via Affinity‐Filtering Strategy | |
| Soliman et al. | Responsive polyelectrolyte complexes for triggered release of nucleic acid therapeutics | |
| Lee et al. | Protein cages engineered for interaction-driven selective encapsulation of biomolecules | |
| WO2016197264A1 (zh) | 一种结合异核苷修饰、末端肽缀合及阳离子脂质体的小干扰rna修饰方法及制剂 | |
| Ojha et al. | Virus as a nanocarrier for drug delivery redefining medical therapeutics-a status report | |
| Khorenko et al. | Foscarnet-type inorganic-organic hybrid nanoparticles for effective antiviral therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |